论文部分内容阅读
目的 :观察消化道恶性肿瘤患者血浆尿激酶型纤溶酶原激活物 ( u- PA)及其特异性受体 ( u- PAR)和纤溶酶原激活物抑制物 - 1 ( PAI- 1 )含量的变化及其与肿瘤转移和预后的关系。方法 :用 ELISA法测定 43例消化道恶性肿瘤患者和 2 1例正常人血浆中 u- PA、u-PAR和 PAI- 1含量。结果 :食管癌、胃癌和结肠癌患者的血浆 u- PA、u- PAR和 PAI- 1含量均显著升高 ;肿瘤组中 ,中、晚期组 u- PA显著高于早期组 ,已转移组 u- PA、u- PAR和 PAI- 1较未转移组显著升高。结论 :消化道恶性肿瘤患者血浆中 u- PA、u- PAR和 PAI- 1含量不同程度升高 ,并与肿瘤转移和预后相关
Objective: To observe the changes of plasma urokinase-type plasminogen activator (u-PA), its specific receptor (u- PAR) and plasminogen activator inhibitor-1 (PAI- 1) in patients with gastrointestinal cancer. Content changes and its relationship with tumor metastasis and prognosis. Methods: The levels of u-PA, u-PAR and PAI-1 in 43 patients with gastrointestinal cancer and 21 normal controls were measured by ELISA. Results: The levels of u-PA, u-PAR and PAI-1 in esophageal cancer, gastric cancer and colon cancer patients were significantly higher than those in the early stage and metastasis group - PA, u-PAR and PAI-1 were significantly higher than the non-metastasis group. Conclusion: The levels of u-PA, u-PAR and PAI-1 in patients with gastrointestinal cancer are increased to varying degrees, which are correlated with tumor metastasis and prognosis